Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2020-04-10 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于公司会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding a change in accounting policies. It details the reasons for the change, the new accounting standards being adopted, and the impact on the company's financials. It also includes opinions from independent directors and the supervisory board approving the change. The document is relatively short (1478 characters) and does not contain actual financial statements or detailed financial data. It is an announcement about a change in accounting policy rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-04-10 Chinese
关于集中竞价回购公司股份通知债权人的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding a share repurchase plan through centralized bidding. It details the reasons for the repurchase, the amount of funds allocated, the intended use of repurchased shares (cancellation and employee incentive plan), and instructions for creditors to declare their claims. The document is a notification to creditors about the company's share buyback and related legal rights, not a financial report or earnings release. It is not an annual or interim report, nor a management discussion or earnings release. It is a formal announcement about the company's share repurchase activity, which fits the category of Transaction in Own Shares (POS). The document length is about 2000 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is POS with high confidence.
2020-04-08 Chinese
2020年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2020 third extraordinary general meeting of shareholders of Kunming Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results on specific proposals, and legal witness statements. The content focuses on the voting outcomes and procedural compliance rather than presenting financial data or detailed reports. The document length is about 2000 characters, which is relatively short and typical for a voting results announcement. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-04-08 Chinese
2020年第三次临时股东大会的法律意见
Legal Proceedings Report Classification · 90% confidence The document is a legal opinion issued by a law firm regarding the procedures, attendance, and validity of a specific shareholders' meeting (the 2020 third extraordinary general meeting) of Kunming Pharmaceutical Group Co., Ltd. It details the convening, attendance, voting procedures, and results of the meeting. The document does not contain financial statements or financial performance data, nor is it a transcript or presentation. It is not an announcement of voting results but a legal opinion on the meeting's compliance and validity. Given the nature of the document as a legal opinion related to a shareholders' meeting, it best fits under Legal Proceedings Report (LTR), which covers updates on significant legal matters involving the company, including legal opinions on corporate governance events.
2020-04-08 Chinese
关于公司全资子公司昆药集团医药商业有限公司之子公司业绩承诺实现及业绩补偿情况的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the performance commitment realization and compensation progress related to its wholly-owned subsidiary's acquisition of another company. It details the original performance commitments, actual audited net profits for 2017-2019, the shortfall in meeting those commitments, and the compensation paid by the original shareholders to the subsidiary. The document is a progress announcement about a transaction and related performance compensation, not a full financial report, audit report, or earnings release. It does not contain comprehensive financial statements or detailed financial analysis but rather a specific update on a transaction-related performance commitment and compensation. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-04-07 Chinese
关于回购股份事项前十大股东和前十大无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the company's share repurchase plan and the disclosure of the top 10 shareholders and top 10 unrestricted shareholders as of the record date for the third extraordinary general meeting in 2020. It references a previous announcement about the share repurchase plan and provides detailed shareholding information. The content focuses on shareholding and share repurchase matters rather than financial results, management changes, or regulatory filings. Given the focus on share repurchase and shareholder holdings, this fits the category of Transaction in Own Shares (POS). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2020-04-02 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.